Evidence map›Paper›PMID 20085661›Full record

ArticleBMC neuroscience2010

Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.

Aaron G Filler, Garth T Whiteside, Mark Bacon, Martyn Frederickson, Franklyn A Howe, Miri D Rabinowitz, Alan J Sokoloff, Terrence W Deacon, Chris Abell, Raj Munglani and 3 more

Abstract read
In one paragraph

Article in BMC neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Nanoparticle-mediated signaling endosome localization regulates growth cone motility and neurite growth.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Aaron G FillerInstitute for Nerve Medicine, 2716 Ocean Park Blvd,, Suite 3082, Santa Monica, CA 90405, USA. afiller@nervemed.com
Garth T Whiteside
Mark Bacon
Martyn Frederickson
Franklyn A Howe
Miri D Rabinowitz
Alan J Sokoloff
Terrence W Deacon
Chris Abell
Raj Munglani
John R Griffiths
B Anthony Bell
Andrew M L Lever

Funding

Cancer Research UK 11562
6 · The paper itself

Abstract

backgroundTargeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodics, and neuroprotectants. Systemic side effects or undesirable effects on parts of the CNS that are not involved in the pathology limit efficacy and limit clinical utility for many classes of pharmaceuticals. Axonal transport from the periphery offers a possible selective route, but there has been little progress towards design of agents that can accomplish targeted delivery via this intraneural route. To achieve this goal, we developed a tripartite molecular construction concept involving an axonal transport facilitator molecule, a polymer linker, and a large number of drug molecules conjugated to the linker, then sought to evaluate its neurobiology and pharmacological behavior.

resultsWe developed chemical synthesis methodologies for assembling these tripartite complexes using a variety of axonal transport facilitators including nerve growth factor, wheat germ agglutinin, and synthetic facilitators derived from phage display work. Loading of up to 100 drug molecules per complex was achieved. Conjugation methods were used that allowed the drugs to be released in active form inside the cell body after transport. Intramuscular and intradermal injection proved effective for introducing pharmacologically effective doses into selected populations of CNS neurons. Pharmacological efficacy with gabapentin in a paw withdrawal latency model revealed a ten fold increase in half life and a 300 fold decrease in necessary dose relative to systemic administration for gabapentin when the drug was delivered by axonal transport using the tripartite vehicle.

conclusionSpecific targeting of selected subpopulations of CNS neurons for drug delivery by axonal transport holds great promise. The data shown here provide a basic framework for the intraneural pharmacology of this tripartite complex. The pharmacologically efficacious drug delivery demonstrated here verify the fundamental feasibility of using axonal transport for targeted drug delivery.

Indexed as

Axonal TransportAminesAnalgesicsAnimalsCell LineCells, CulturedCricetinaeCyclohexanecarboxylic AcidsDextransDose-Response Relationship, DrugDrug Delivery SystemsGabapentingamma-Aminobutyric AcidHalf-LifeMacaca fascicularisModels, NeurologicalAminesAnalgesicsCyclohexanecarboxylic AcidsDextransGabapentingamma-Aminobutyric AcidNerve Growth FactorPolymersWheat Germ Agglutinins

Identifiers

PMID20085661
PMCPMC2837052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.